United Therapeutics Corp. (UTHR) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1162232,
    "name": "United Therapeutics Corp.",
    "stock_name": "United Therapeutics Corp.",
    "full_name": "United Therapeutics Corp.",
    "name_url": "stocks-analysis/united-therapeutics-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "484.10",
    "chg": 9.96,
    "chgp": "2.1%",
    "dir": 1,
    "prev_price": "474.14",
    "mcapval": "28,351.66",
    "mcap": "Mid Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US91307C1027",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.26 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/united-therapeutics-corp-1162232-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "United Therapeutics Hits Day High with 9.63% Surge in Stock Price",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/united-therapeutics-hits-day-high-with-963-surge-in-stock-price-3659294",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/UnitedTherapeut_priceRelatedfactors_3659294.png",
        "date": "2025-10-30 19:25:56",
        "description": "United Therapeutics Corp. has seen notable stock activity, achieving an intraday high of USD 479.50. The company has demonstrated strong performance over various periods, with significant returns and positive financial metrics, including a high return on equity and consistent profitability over the last eight quarters."
      },
      {
        "title": "United Therapeutics Corp. Hits New 52-Week High of $479.50",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/united-therapeutics-corp-hits-new-52-week-high-of-47950-3659093",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/UnitedTherapeut_priceRelatedfactors_3659093.png",
        "date": "2025-10-30 18:25:53",
        "description": "United Therapeutics Corp. achieved a new 52-week high of USD 479.50 on October 29, 2025, reflecting strong performance in the pharmaceuticals sector. The company has seen a significant stock price increase over the past year, supported by solid fundamentals, positive cash flow, and financial stability."
      },
      {
        "title": "United Therapeutics Corp. Experiences Revision in Stock Evaluation Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/united-therapeutics-corp-technical-trend-shifts-from-bullish-to-mildly-bullish-amid-stock-price-decline-3652076",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/UnitedTherapeut_technicaldot_3652076.png",
        "date": "2025-10-28 15:39:44",
        "description": "United Therapeutics Corp. has recently adjusted its evaluation amid changing market conditions. The company's stock is priced at $421.04, reflecting a solid 20.23% return over the past year, outperforming the S&P 500. Its five-year performance shows a remarkable 242.92% return, highlighting its resilience in the pharmaceutical sector."
      },
      {
        "title": "Is United Therapeutics Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-united-therapeutics-corp-technically-bullish-or-bearish-3647786",
        "imagepath": "",
        "date": "2025-10-27 11:51:53",
        "description": "As of 24 October 2025, the technical trend for United Therapeutics Corp. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD also indicates bullishness. However, the weekly and monthly RSI readings are bearish, suggesting some weakness. The Bollinger Bands are mildly bullish on both weekly and monthly time frames. Daily moving averages are bullish, but the KST shows a mixed picture with weekly bullishness and monthly mild bearishness. Dow Theory indicates a mildly bearish stance weekly, but bullish monthly, and the OBV is mildly bearish weekly while bullish monthly.\n\nIn terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -3.41% and -4.60% compared to the S&P 500's gains of 1.92% and 2.32%, respectively. However, it has outperformed the benchmark year-to-date and over longer periods, with a YTD return of 18.63..."
      },
      {
        "title": "Is United Therapeutics Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-united-therapeutics-corp-technically-bullish-or-bearish-3646321",
        "imagepath": "",
        "date": "2025-10-26 11:26:32",
        "description": "As of 24 October 2025, the technical trend for United Therapeutics Corp. has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish, indicating positive momentum. However, the RSI shows bearish signals on both the weekly and monthly time frames, suggesting potential weakness. Bollinger Bands are mildly bullish in both weekly and monthly assessments, supporting a cautious upward outlook. Daily moving averages are bullish, which adds to the positive sentiment. KST is bullish weekly but mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly stance while being bullish monthly. OBV reflects a mildly bearish weekly trend but is bullish monthly.\n\nIn terms of performance, United Therapeutics has outperformed the S&P 500 year-to-date with an 18.63% return compared to 15.47% for the index, and over the past year, it has returned 19.53% versus ..."
      },
      {
        "title": "United Therapeutics Corp. Hits New 52-Week High of $459.48",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/united-therapeutics-corp-hits-new-52-week-high-of-45948-3604284",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/UnitedTherapeut_priceRelatedfactors_3604284.png",
        "date": "2025-10-08 16:40:52",
        "description": "United Therapeutics Corp. has achieved a new 52-week high, reflecting its strong performance with a notable return over the past year. The company demonstrates operational efficiency with a solid return on equity and a low debt-to-equity ratio, alongside impressive operating cash flow and profit figures."
      },
      {
        "title": "United Therapeutics Corp. Hits New 52-Week High of $455.26",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/united-therapeutics-corp-hits-new-52-week-high-of-45526-3601581",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/UnitedTherapeut_priceRelatedfactors_3601581.png",
        "date": "2025-10-07 21:43:34",
        "description": "United Therapeutics Corp. has achieved a new 52-week high, reflecting its strong performance with a one-year return significantly exceeding the S&P 500. The company showcases robust operational efficiency, a solid balance sheet, and consistent positive results over the last eight quarters, highlighting its commitment to growth in the pharmaceuticals sector."
      },
      {
        "title": "United Therapeutics Corp. Hits New 52-Week High of $455.00",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/united-therapeutics-corp-hits-new-52-week-high-of-45500-3595586",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/UnitedTherapeut_priceRelatedfactors_3595586.png",
        "date": "2025-10-06 17:27:51",
        "description": "United Therapeutics Corp. has achieved a new 52-week high, reflecting its strong performance with a one-year return significantly above the S&P 500. The company showcases robust operational efficiency, a solid balance sheet, and positive financial results, indicating strong long-term fundamentals in the biotechnology sector."
      },
      {
        "title": "United Therapeutics Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/united-therapeutics-corp-technical-trend-upgrades-from-mildly-bullish-to-bullish-amid-stock-price-increase-3579834",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/UnitedTherapeut_technicaldot_3579834.png",
        "date": "2025-09-29 16:01:51",
        "description": "United Therapeutics Corp. has experienced notable shifts in its technical indicators, with its stock price currently at 432.66. The company has shown strong performance, significantly outperforming the S&P 500 over various timeframes, including a remarkable 39.92% return in the past month and a 330.72% return over five years."
      }
    ],
    "total": 19,
    "sid": "1162232",
    "stock_news_url": "https://www.marketsmojo.com/news/united-therapeutics-corp-1162232"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

United Therapeutics Hits Day High with 9.63% Surge in Stock Price

2025-10-30 19:25:56

United Therapeutics Corp. has seen notable stock activity, achieving an intraday high of USD 479.50. The company has demonstrated strong performance over various periods, with significant returns and positive financial metrics, including a high return on equity and consistent profitability over the last eight quarters.

United Therapeutics Corp. Hits New 52-Week High of $479.50

2025-10-30 18:25:53

United Therapeutics Corp. achieved a new 52-week high of USD 479.50 on October 29, 2025, reflecting strong performance in the pharmaceuticals sector. The company has seen a significant stock price increase over the past year, supported by solid fundamentals, positive cash flow, and financial stability.

United Therapeutics Corp. Experiences Revision in Stock Evaluation Amid Strong Market Performance

2025-10-28 15:39:44

United Therapeutics Corp. has recently adjusted its evaluation amid changing market conditions. The company's stock is priced at $421.04, reflecting a solid 20.23% return over the past year, outperforming the S&P 500. Its five-year performance shows a remarkable 242.92% return, highlighting its resilience in the pharmaceutical sector.

Is United Therapeutics Corp. technically bullish or bearish?

2025-10-27 11:51:53

As of 24 October 2025, the technical trend for United Therapeutics Corp. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD also indicates bullishness. However, the weekly and monthly RSI readings are bearish, suggesting some weakness. The Bollinger Bands are mildly bullish on both weekly and monthly time frames. Daily moving averages are bullish, but the KST shows a mixed picture with weekly bullishness and monthly mild bearishness. Dow Theory indicates a mildly bearish stance weekly, but bullish monthly, and the OBV is mildly bearish weekly while bullish monthly. In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -3.41% and -4.60% compared to the S&P 500's gains of 1.92% and 2.32%, respectively. However, it has outperformed the benchmark year-to-date and over longer periods, with a YTD return of 18.63...

Is United Therapeutics Corp. technically bullish or bearish?

2025-10-26 11:26:32

As of 24 October 2025, the technical trend for United Therapeutics Corp. has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish, indicating positive momentum. However, the RSI shows bearish signals on both the weekly and monthly time frames, suggesting potential weakness. Bollinger Bands are mildly bullish in both weekly and monthly assessments, supporting a cautious upward outlook. Daily moving averages are bullish, which adds to the positive sentiment. KST is bullish weekly but mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly stance while being bullish monthly. OBV reflects a mildly bearish weekly trend but is bullish monthly. In terms of performance, United Therapeutics has outperformed the S&P 500 year-to-date with an 18.63% return compared to 15.47% for the index, and over the past year, it has returned 19.53% versus ...

United Therapeutics Corp. Hits New 52-Week High of $459.48

2025-10-08 16:40:52

United Therapeutics Corp. has achieved a new 52-week high, reflecting its strong performance with a notable return over the past year. The company demonstrates operational efficiency with a solid return on equity and a low debt-to-equity ratio, alongside impressive operating cash flow and profit figures.

United Therapeutics Corp. Hits New 52-Week High of $455.26

2025-10-07 21:43:34

United Therapeutics Corp. has achieved a new 52-week high, reflecting its strong performance with a one-year return significantly exceeding the S&P 500. The company showcases robust operational efficiency, a solid balance sheet, and consistent positive results over the last eight quarters, highlighting its commitment to growth in the pharmaceuticals sector.

United Therapeutics Corp. Hits New 52-Week High of $455.00

2025-10-06 17:27:51

United Therapeutics Corp. has achieved a new 52-week high, reflecting its strong performance with a one-year return significantly above the S&P 500. The company showcases robust operational efficiency, a solid balance sheet, and positive financial results, indicating strong long-term fundamentals in the biotechnology sector.

United Therapeutics Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators

2025-09-29 16:01:51

United Therapeutics Corp. has experienced notable shifts in its technical indicators, with its stock price currently at 432.66. The company has shown strong performance, significantly outperforming the S&P 500 over various timeframes, including a remarkable 39.92% return in the past month and a 330.72% return over five years.

View All News